Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline
Neuro-Oncology · 03.10.2023 · 25 (10) · 1731-1749
DOI: 10.1093/neuonc/noad100 ↗Kurz gefasst
Leitlinie in der Zeitschrift Neuro-Oncology, online erschienen am 02.06.2023. Verfasst von Felix Sahm und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 117-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In the 5th edition of the WHO CNS tumor classification (CNS5, 2021), multiple molecular characteristics became essential diagnostic criteria for many additional CNS tumor types. For those tumors, an integrated, “histomolecular” diagnosis is required. A variety of approaches exists for determining the status of the underlying molecular markers. The present guideline focuses on the methods that can be used for assessment of the currently most informative diagnostic and prognostic molecular markers for the diagnosis of gliomas, glioneuronal and neuronal tumors. The main characteristics of the molecular methods are systematically discussed, followed by recommendations and information on available evidence levels for diagnostic measures. The recommendations cover DNA and RNA next-generation-sequencing, methylome profiling, and select assays for single/limited target analyses, including immunohistochemistry. Additionally, because of its importance as a predictive marker in IDH-wildtype glioblastomas, tools for the analysis of MGMT promoter methylation status are covered. A structured overview of the different assays with their characteristics, especially their advantages and limitations, is provided, and requirements for input material and reporting of results are clarified. General aspects of molecular diagnostic testing regarding clinical relevance, accessibility, cost, implementation, regulatory, and ethical aspects are discussed as well. Finally, we provide an outlook on new developments in the landscape of molecular testing technologies in neuro-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
- CCU Neuropathology, German Concortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology and Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation T…
- Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
- Department of Neuropathology, Charité, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Felix Sahm, Sebastian Brandner, Luca Bertero, David Capper, Pim J French, Dominique Figarella-Branger, Christine Haberler, Monika E Hegi, Bjarne W Kristensen, Kathreena M Kurian, Matthias Preusser, Bastiaan B J Tops, Martin van den Bent, Wolfgang Wick, Pieter Wesseling
Zitieren
APA
Sahm, F., Brandner, S., Bertero, L., Capper, D., French, P. J., Figarella-Branger, D., Giangaspero, F., Haberler, C., Hegi, M. E., Kristensen, B. W., Kurian, K. M., Preusser, M., Tops, B. B. J., van den Bent, M., Wick, W., Reifenberger, G., & Wesseling, P. (2023). Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro-Oncology, 25(10), 1731-1749. https://doi.org/10.1093/neuonc/noad100
Vancouver
Sahm F, Brandner S, Bertero L, Capper D, French PJ, Figarella-Branger D, et al. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro-Oncology. 2023;25(10):1731-1749. doi:10.1093/neuonc/noad100
BibTeX
@article{Sahm2023,
author = {Sahm, Felix and Brandner, Sebastian and Bertero, Luca and Capper, David and French, Pim J and Figarella-Branger, Dominique and Giangaspero, Felice and Haberler, Christine and Hegi, Monika E and Kristensen, Bjarne W and Kurian, Kathreena M and Preusser, Matthias and Tops, Bastiaan B J and van den Bent, Martin and Wick, Wolfgang and Reifenberger, Guido and Wesseling, Pieter},
title = {Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {10},
pages = {1731--1749},
doi = {10.1093/neuonc/noad100}
}
EUVIMED